This repository contains the R scripts used for the analysis of the research paper titled "**PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma**".
https://pubmed.ncbi.nlm.nih.gov/38171116/
Please cite: Ellebaek, E., Khan, S., Bastholt, L., Schmidt, H., Haslund, C. A., Donia, M., & Svane, I. M. (2024). PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. European Journal of Cancer, 198, 113476.

## Contact
Please contact us:

Shawez Khan: shawez.khan@regionh.dk

Marco Donia: marco.donia@regionh.dk
